Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

BioSpace

Biogen, Eli Lilly, Merck and Novartis spent more than $20 billion to absorb biotechs with promising or approved drugs; the rare disease space notched approvals for therapies from Denali Therapeutics,

M&A / DealsRare DiseaseRead full story